Spots Global Cancer Trial Database for refractory metastatic colorectal cancer
Every month we try and update this database with for refractory metastatic colorectal cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC | NCT02860546 | Refractory Meta... | TAS-102 nivolumab | 18 Years - | Taiho Oncology, Inc. | |
| NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer | NCT05213195 | Refractory Meta... | NKG2D CAR-NK | 18 Years - 70 Years | Zhejiang University | |
| QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer | NCT04527068 | Refractory Meta... pMMR MSS | Bevacizumab Tripleitriumab | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients | NCT05205330 | Refractory Meta... Solid Tumor Metastatic Micr... Mismatch Repair... | CR6086 AGEN2034 | 18 Years - | Rottapharm Biotech | |
| QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer | NCT04527068 | Refractory Meta... pMMR MSS | Bevacizumab Tripleitriumab | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer | NCT05248048 | Refractory Meta... | CAR-T infusion | 18 Years - 75 Years | The Third Affiliated Hospital of Guangzhou Medical University | |
| RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | NCT05733611 | Refractory Meta... pMMR MSS | RP2 RP3 atezolizumab bevacizumab | 18 Years - | Replimune Inc. | |
| Azacitidine and CAPOX in Metastatic Colorectal Cancer | NCT01193517 | Colorectal Canc... | Azacitidine Capecitabine Oxaliplatin Azacitidine MTD | 18 Years - | M.D. Anderson Cancer Center | |
| NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer | NCT05213195 | Refractory Meta... | NKG2D CAR-NK | 18 Years - 70 Years | Zhejiang University | |
| RE-SEARCH Study: A Study to Learn How and in Which Amount Regorafenib is Given in Usual Practice to Patients in Spain: a Study Looking Back at Cases That Have Already Happened When the Study Begins. | NCT04920422 | Metastatic Colo... | No intervention | 18 Years - | Bayer | |
| QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer | NCT04527068 | Refractory Meta... pMMR MSS | Bevacizumab Tripleitriumab | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| RE-SEARCH Study: A Study to Learn How and in Which Amount Regorafenib is Given in Usual Practice to Patients in Spain: a Study Looking Back at Cases That Have Already Happened When the Study Begins. | NCT04920422 | Metastatic Colo... | No intervention | 18 Years - | Bayer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
